On September 8, 2022 OncoBone Ventures (www.oncoboneventures.com), a UK start-up biotech company seeking to develop novel therapies for cancer patients with currently incurable bone metastases, reported the signing of Co-operation Framework Agreements ("Agreements") with three partners ("Partners"), Okayama University in Japan (www.okayama-u.ac.jp), University of Bradford in UK (www.bradford.ac.uk) and The Development Center for Biotechnology (DCB) in Taiwan (www.dcb.org.tw) (Press release, OncoBone Ventures, SEP 8, 2022, View Source [SID1234636483]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Agreements include preclinical testing of therapeutic assets developed by Partners for the treatment of cancer. The role of OncoBone Ventures will be to evaluate the efficacy of the therapeutic assets in preclinical bone metastasis models, followed by safety assessments for those assets that demonstrate good efficacy for bone metastases.

Dr. Jussi Halleen, CEO of OncoBone Ventures comments: "We are delighted to have signed these Co-operation Agreements with such prestigious institutions. The Agreements will provide a consistent basis for our future co-operation with the Partners within an agreed framework."